{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02658",
      "entity_text" : "Xa inhibitors",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q16473",
      "entity_text" : "Xa",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0800" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "XREF_BIBR Andexanet alfa, a recombinant factor Xa molecule, which can bind both to direct factor Xa inhibitors (such as rivaroxaban, apixaban, and edoxaban) and to factor Xa inhibitors that require antithrombin activity (such as low molecular weight heparin and fondaparinux), was also approved recently.",
  "reading_complete" : "2020-08-04T14:03:41Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T14:02:39Z",
  "trigger" : "bind",
  "evidence" : [ "Xa molecule, which can bind both to direct factor Xa inhibitors (such as rivaroxaban, apixaban, and edoxaban) and to factor Xa inhibitors" ],
  "pmc_id" : "6375259",
  "score" : 0
}